Apellis and Sobi report data from Phase II C3 glomerulopathy trial
Pegcetacoplan treatment resulted in sustained improvements in proteinuria and kidney function stabilisation.
Source: yahoo.com
Caroline Baumal News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Caroline Baumal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Caroline Baumal Today - Breaking & Trending Today
Pegcetacoplan Offers Potential Benefit in Post-Transplant C3G, IC-MPGN
The phase 2 NOBLE trial shows pegcetacoplan reduces disease activity in post-transplant C3G and IC-MPGN, with benefits persisting through the 40-week double-blind period.
Source: hcplive.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $77.93 Consensus Target Price from Brokerages
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to […]
Source: dailypolitical.com
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that leading retina specialist P...
Source: businessinsider.com
Polar Capital Holdings Plc Grows Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Polar Capital Holdings Plc increased its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 126.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,053,875 shares of the company’s stock after acquiring an additional 588,875 shares during the quarter. […]
Source: dailypolitical.com